Epithelial junction opener JO-1 improves monoclonal antibody therapy of cancer
about
Approaches to improve tumor accumulation and interactions between monoclonal antibodies and immune cellsDesmosome regulation and signaling in diseaseFunctional characterisation of the WW minimal domain for delivering therapeutic proteins by adenovirus dodecahedronThe Structural Basis for the Integrity of Adenovirus Ad3 DodecahedronStructural and Functional Studies on the Interaction of Adenovirus Fiber Knobs and Desmoglein 2Spheroids of HER2-Positive Breast Adenocarcinoma for Studying Anticancer Immunotoxins In Vitro.Incorporating target-mediated drug disposition in a minimal physiologically-based pharmacokinetic model for monoclonal antibodies.Penton-dodecahedral particles trigger opening of intercellular junctions and facilitate viral spread during adenovirus serotype 3 infection of epithelial cells.Identification of reproducible gene expression signatures in lung adenocarcinoma.Desmoglein 2 depletion leads to increased migration and upregulation of the chemoattractant secretoneurin in melanoma cells.Adenoviruses using the cancer marker EphA2 as a receptor in vitro and in vivo by genetic ligand insertion into different capsid scaffolds.Preclinical safety and efficacy studies with an affinity-enhanced epithelial junction opener and PEGylated liposomal doxorubicin.A new human DSG2-transgenic mouse model for studying the tropism and pathology of human adenoviruses.Intracellular Signaling and Desmoglein 2 Shedding Triggered by Human Adenoviruses Ad3, Ad14, and Ad14P1.Epithelial Junction Opener Improves Oncolytic Adenovirus Therapy in Mouse Tumor ModelsCleavage of transmembrane junction proteins and their role in regulating epithelial homeostasis.Strategies to increase drug penetration in solid tumors.Overcoming physical barriers in cancer therapy.Roles of the first-generation claudin binder, Clostridium perfringens enterotoxin, in the diagnosis and claudin-targeted treatment of epithelium-derived cancers.Genetically encoded immunophotosensitizer 4D5scFv-miniSOG is a highly selective agent for targeted photokilling of tumor cells in vitro.Claudin-targeted drug development using anti-claudin monoclonal antibodies to treat hepatitis and cancer.Coadministration of epithelial junction opener JO-1 improves the efficacy and safety of chemotherapeutic drugs.Improving drug uptake and penetration into tumors: current and forthcoming opportunities.2nd PEGS Annual Symposium on Antibodies for Cancer Therapy: April 30-May 1, 2012, Boston, USA.The Effect of the Targeted Recombinant Toxin DARPin-PE40 on the Dynamics of HER2-Positive Tumor Growth.Junction opener protein increases nanoparticle accumulation in solid tumors.Modeling the effects of space structure and combination therapies on phenotypic heterogeneity and drug resistance in solid tumors.Tumor Restrictions to Oncolytic Virus.Mapping of Adenovirus of serotype 3 fibre interaction to desmoglein 2 revealed a novel 'non-classical' mechanism of viral receptor engagement.Designer Oncolytic Adenovirus: Coming of Age.Human adenovirus type 17 from species D transduces endothelial cells and human CD46 is involved in cell entry
P2860
Q26852287-59E0AEA9-BDDE-4610-A9E8-B1E657E41440Q27013675-C4C09370-1665-4723-9635-F83444396F0FQ27318180-64A7A05A-144E-49EA-970E-B1C72F65433BQ27674368-A87B748C-1881-41ED-8797-E77723D1BAD9Q27679683-2BB3EAFD-F097-46E8-977F-4EE60E159D5BQ33607808-16F1C243-5EFE-4480-8B05-E28BD14251EBQ34204024-CB2D3421-5B1D-4A23-A9AA-8C060CBA3049Q35034232-5F0D88B9-52E9-4456-B852-9D54F4F526E8Q35076226-7097073E-142E-4886-A705-BF5C93FA6AF1Q35099880-BEB7014A-964C-4BB1-8EDF-50D31A939136Q35156188-A5B5449C-4ED4-4190-BEC3-AAF4950A472AQ35651085-BB82B3E1-B962-48E6-AFF8-110C689C52EDQ36023115-D3B32026-52C6-40C9-90C5-2B6C7BB4D5DAQ36208218-D0845F59-76D8-4B7B-9287-8357DC44FB22Q36825407-EA0121F8-9237-4B6F-BDAE-EB37CB5C37EDQ37428089-3FF02C9A-2976-49A0-97D0-CAB84CCB7418Q38125197-8B7D9089-FB5A-4A95-9BCF-02CA670328EEQ38318962-BFD185EA-3C88-40D8-90B0-6CF39D4EE3ACQ38821198-C1D47FB4-60B1-4EFA-8C33-E1E20AE147F5Q39047491-A1B33280-A6DC-4C65-88A7-45815B8EB210Q39246243-02127971-381F-4394-B329-0E0DE127E727Q39358604-A3086B61-52D6-4753-AD0D-8646E0FBA05AQ41861892-CA195CB0-9543-4A78-9B53-AC7AFF7890FCQ42333514-F4752681-F710-41F5-B875-FAB17C545C39Q46448172-B06DC1CE-1A20-4C82-BED2-7120B39D3010Q47197354-0F9E8E89-F7C3-4312-983B-FFCCECB50E6AQ50998666-FBFC662F-42B5-42A5-9D83-AAF64D257CD8Q51846287-777525BA-16C9-46AD-A394-54EB28CF9116Q54948734-620FC10C-E8BF-4CC8-BCFE-E8400DE29325Q55467684-B063BB29-EF68-4572-866A-DF97D619CE35Q58759854-357D3C4C-06A7-48EE-8414-6C5DF0B7402B
P2860
Epithelial junction opener JO-1 improves monoclonal antibody therapy of cancer
description
2011 nî lūn-bûn
@nan
2011 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Epithelial junction opener JO-1 improves monoclonal antibody therapy of cancer
@ast
Epithelial junction opener JO-1 improves monoclonal antibody therapy of cancer
@en
type
label
Epithelial junction opener JO-1 improves monoclonal antibody therapy of cancer
@ast
Epithelial junction opener JO-1 improves monoclonal antibody therapy of cancer
@en
prefLabel
Epithelial junction opener JO-1 improves monoclonal antibody therapy of cancer
@ast
Epithelial junction opener JO-1 improves monoclonal antibody therapy of cancer
@en
P2093
P2860
P1433
P1476
Epithelial junction opener JO-1 improves monoclonal antibody therapy of cancer
@en
P2093
André Lieber
Hongjie Wang
Ines Beyer
Jonas Persson
Qinghua Feng
Robert Strauss
Roma Yumul
Ruan van Rensburg
P2860
P304
P356
10.1158/0008-5472.CAN-11-2009
P407
P577
2011-10-11T00:00:00Z